Literature DB >> 15471953

Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha.

Hilit Gur1, Rita Krauthgamer, Esther Bachar-Lustig, Helena Katchman, Rinat Arbel-Goren, Alain Berrebi, Tirza Klein, Arnon Nagler, Antonio Tabilio, Massimo F Martelli, Yair Reisner.   

Abstract

Previous studies suggest that cells within the CD34(+) hematopoietic stem cell compartment are endowed with immune regulatory activity. Furthermore, it is possible to expand the human regulatory cells upon short-term culture of purified CD34+ cells with an early-acting cytokine cocktail. We now show that addition of anti-CD28, anti-CD2, interleukin-2 (IL-2), anti-IL-10, or IL-12 to the bulk mixed lymphocyte reaction (MLR) cannot reverse the inhibitory activity of the CD34+ cells, ruling out anergy-based mechanisms or mechanisms involving Th1-Th2 skewing. Furthermore, phenotyping of cells present after addition of CD34+ cells to the bulk MLR ruled out potential induction of plasmacytoid dendritic precursors, known to be endowed with regulatory activity. In contrast, the inhibitory activity of CD34+ cells could be reversed by adding the caspase inhibitor BD-FMK to the bulk MLR, indicating a deletion-based mechanism. The deletion can be inhibited by anti-tumor necrosis factor-alpha (anti-TNF-alpha) and not by anti-transforming growth factor-beta (anti-TGF-beta), suggesting a potential role for TNF-alpha in the regulatory activity of CD34+ cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471953     DOI: 10.1182/blood-2002-11-3463

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Authors:  Eran Ophir; Yaki Eidelstein; Ran Afik; Esther Bachar-Lustig; Yair Reisner
Journal:  Blood       Date:  2009-12-30       Impact factor: 22.113

2.  T-cell depletion: from positive selection to negative depletion in adult patients.

Authors:  F Aversa
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

3.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 4.  Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

5.  Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide.

Authors:  Franco Aversa; Esther Bachar-Lustig; Noga Or-Geva; Lucia Prezioso; Sabrina Bonomini; Ilenia Manfra; Alessandro Monti; Chiara Schifano; Yael Zlotnikov-Klionsky; Massimo F Martelli; Gabriella Sammarelli; Maria Sassi; Maurizio Soli; Silvia Giuliodori; Magda Benecchi; Nicola Giuliani; Frank Lohr; Silvia Pratissoli; Yair Reisner
Journal:  Blood Adv       Date:  2017-10-30

Review 6.  Immunological applications of stem cells in type 1 diabetes.

Authors:  Paolo Fiorina; Julio Voltarelli; Nicholas Zavazava
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

7.  Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.

Authors:  Paolo Fiorina; Mollie Jurewicz; Andrea Vergani; Alessandra Petrelli; Michele Carvello; Francesca D'Addio; Jonathan G Godwin; Kenneth Law; Erxi Wu; Ze Tian; Gebhard Thoma; Jiri Kovarik; Stefano La Rosa; Carlo Capella; Scott Rodig; Hans-Guenter Zerwes; Mohamed H Sayegh; Reza Abdi
Journal:  J Immunol       Date:  2010-12-03       Impact factor: 5.422

8.  CD4+CD25+ T regulatory cells induced by LPS-activated bone marrow dendritic cells suppress experimental autoimmune uveoretinitis in vivo.

Authors:  Kirsten Siepmann; Sabine Biester; Jarmila Plsková; Elizabeth Muckersie; Linda Duncan; John V Forrester
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02       Impact factor: 3.117

9.  Hematopoietic stem cell transplantation across major genetic barriers.

Authors:  Yair Reisner
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  The use of donor-derived veto cells in hematopoietic stem cell transplantation.

Authors:  Eran Ophir; Yair Reisner
Journal:  Front Immunol       Date:  2012-05-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.